Focal spasticity is a medical disorder characterized by an abnormal increase in muscular stiffness in one or more muscles, and usually is the result of a brain or spinal cord injury. Such injury may affect movement control and impair daily activities. Spasticity may be linked to multiple sclerosis, cerebral palsy, spinal cord injury, stroke, and brain or head trauma.
The degree of spasticity ranges from mild muscle stiffness to severe, painful and uncontrollable muscle spasms. In the lower limbs, spasticity usually occurs in the gastrocnemius and soleus muscle complex located in the calf. These calf muscles are responsible for walking by raising the heel from the ground.
Increased muscle tone, exaggerated deep tendon reflexes, rapid muscle contractions and/or muscle spasms are some of the clinical symptoms associated with spasticity.
Dysport Therapeutic consists of an injectable form of botulinum toxin type A (BoNT-A), a molecule produced by Clostridium bacteria. Dysport blocks overactive nerve signals, causing contracted muscles to relax.
Positive results from a Phase 3 clinical trial, including 385 patients with lower limb spasticity, dictated Dysport Therapeutic’s regulatory approval.
Patients were randomized to receive Dysport 1,000 units (125 patients), 1,500 units (128 patients), and placebo (128 patients) via intramuscular injection into the gastrocnemius-soleus muscle complex.
Muscle tone was assessed by the Modified Ashworth Scale (MAS) test at the ankle joint (with the knee extended) at week four of treatment.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?